Revenue segments as reported by the company.

Product sales

Royalty, contract and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development expenses

Selling, general and administrative

In-process research and development impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Gilead Sciences reports robust earnings, eyes pipeline opportunities for growth

Gilead Sciences delivered strong financial performance in Q4 2022, driven by growth in key product sales. Despite facing challenges in the HIV market for Q1 2023, the company remains focused on leveraging opportunities in its pipeline and strategic investments.

Gilead reports strong Q1 sales, focuses on pipeline growth

Gilead Sciences delivered strong sales driven by key products in Q1 2023.
While facing challenges like lower Veklury sales, Gilead maintains revenue guidance.
The company's strengths lie in its pipeline, successful products, and manufacturing capabilities.
Opportunities in new indications and therapies position Gilead for future growth.

Gilead Sciences reports robust Q2 performance and eyes future growth

Gilead Sciences had a strong quarter with growth in sales and positive pipeline updates.
Trodelvy's performance in different markets and potential Medicare coverage are key highlights.
Challenges include unsuccessful trials and addressing revenue aspirations.
Opportunities lie in expanding BD activities and exploring cell therapy beyond oncology.

Gilead Sciences reports robust Q3 performance amidst market challenges

Gilead Sciences demonstrated strong performance in Q3 2023, driven by growth in base business, oncology, and HIV segments.
While facing challenges such as declining Veklury sales and barriers to CART therapy uptake, Gilead is actively addressing opportunities for growth and market expansion.
The company's strengths lie in robust product sales, particularly in Biktarvy and Trodelvy, with a focus on innovation and strategic positioning in key therapeutic areas.
Overall, Gilead's performance reflects resilience and strategic planning amidst evolving market dynamics and competitive landscapes.

Gilead Sciences reports strong 2023 performance, eyes transformative therapies

Gilead Sciences showcased solid performance in 2023 with notable growth in key product sales areas, despite facing challenges in certain clinical trials. The company's strengths lie in its diverse portfolio, pipeline innovation, and commitment to delivering transformative therapies. With a focus on addressing HIV, oncology, and inflammation, Gilead is well-positioned for future growth and success.

Gilead Sciences reports robust Q1 performance and eyes future growth

Gilead Sciences delivered strong Q1 results driven by oncology and HIV product sales.
Challenges include IP R&D charge from Sema Bay acquisition and competitive market dynamics.
Opportunities lie in expanding cell therapy leadership, advancing HIV pipeline, and upcoming pipeline updates.
Overall, Gilead remains focused on growth through innovation and strategic portfolio advancements.

Gilead Sciences reports robust Q3 performance and eyes market expansion

Gilead Sciences' Q3 performance reflects strong revenue growth and market leadership in key segments, supported by successful product launches and strategic initiatives.
The company's focus on innovation, patient-centric approaches, and market expansion bodes well for future growth and competitive positioning.
While challenges in maintaining growth and managing expenses exist, Gilead's proactive stance on addressing market needs and leveraging opportunities positions it for continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

WHO recommended that doctors not recommend GILD's remdesivir pursuant to COVID-19. WHO implied it did not improve survival or need for ventilation.

WHO Throws Shade At Remdesivir

Abbott Labs

AstraZeneca

Inovio Pharmaceuticals

Johnson & Johnson

Novavax

Sorrento Therapeutics Inc

Regeneron Pharmaceuticals

As Pfizer and Moderna take the lead in the novel coronavirus vaccine race, here's how this affects other Covid-19-related biotech stocks. The post 7 Biotech Stocks That Are Locked in the Race for a Vaccine appeared first on InvestorPlace.

7 Biotech Stocks That Are Locked in the Race for a Vaccine

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Johanna Mercier, Chief Commercial Officer, and Merdad Parsey, MD, PhD, Chief Medical Officer, will participate in a fireside chat at the 3rd Annual Evercore ISI HealthCONx Conference on Wednesday, December 2 at 11:20 a.m. Eastern Time. The live webcast can be accessed at the company's investors page at investors.gilead.com. Please connect to the company's website at least 15 minutes prior to the star

Gilead Sciences to Present at the 3rd Annual Evercore ISI HealthCONx Conference on Wednesday, December 2, 2020

Madison Square Garden Entertainment

Ariel Investments recently disclosed its portfolio updates for the third quarter of 2020, which ended on Sept. 30.

Top 3rd-Quarter Trades of John Rogers' Ariel Investments

BioNTech SE

Eli Lilly

Moderna

Pfizer

A COVID-19 vaccine appears to be just around the corner, and many of the companies developing drugs, cocktails, vaccines and treatments are very close to crossing the finish line.

With a Vaccine Coming Soon, Where Do These COVID-19 Stocks Stand?

The company's HIV franchise faces threats from many different directions.

This Company's New Approach Could Slash Gilead's Profit From HIV Drugs

The WHO has recommended against Remdesivir, a popular treatment for COVID-19. Despite this setback, the remainder of the company's asset base remains exciting and its valuation is low.

Bye Bye Remdesivir, Hello Gilead Sciences

The agency concluded there's no evidence that the drug improves survival or positively impacts other outcomes.

WHO Recommends Against Using Gilead's Remdesivir for COVID-19

Gilead's (GILD) remdesivir should not be used for hospitalized COVID-19 patients, as per the WHO's conditional recommendation.

Gilead (GILD) Down on COVID-19 Drug Remdesivir Update

Shares of Eli Lilly & Co. gained 0.6% in premarket trading on Friday, the day after the Food and Drug Administration granted an emergency use authorization to the company's rheumatoid arthritis drug Olumiant as a COVID-19 treatment if it's used in combination with Gilead Sciences Inc.'s Veklury, which is also called remdesivir. The drug combination can be used in adults and children older than 2 years old who have been hospitalized with COVID-19 and require supplemental oxygen, mechanical ventilation, or extracorporeal membrane oxygenation.

Lilly's arthritis drug and Gilead's Veklury receive FDA authorization as combination COVID-19 treatment

The United Nations World Health Organization said Thursday that Gilead Sciences Inc's  (NASDAQ: GILD) remdesivir is not recommended for the treatment of COVID-19, the Wall Street Journal reports.  What Happened: The international agency's panel, which advises it on treatments, made the recommendation against the drug based on data from four global trials which compared the effects of several drugs, according to the Journal.

WHO Advises Against Gilead's Remdesivir For COVID-19 Despite FDA Approval

Shares of Gilead Sciences Inc. fell in after-hours trading Thursday after a World Health Organization panel recommended against doctors using the drug remdesivir to treat coronavirus patients.

WHO advisers recommend against Gilead's remdesivir for treating COVID-19

This is the first drug combination given emergency approval by the FDA for the coronavirus.

FDA Gives Emergency Approval To Covid-19 Treatment That Combines Eli Lilly Arthritis Drug With Remdesivir

Remdesivir was the first coronavirus treatment to receive emergency authorization from the US Food and Drug Administration. Originally developed by pharma giant Gilead Sciences to treat Ebola, the drug has been authorized since May. A study published the same month found that it shortened recovery times for seriously ill COVID-19 patients. Last month, remdesivir earned full FDA approval. 

The WHO will not recommend remdesivir for COVID-19 patients, since it doesn't seem to boost their chances of survival

Dr. Anthony Fauci, the nation's leading infectious disease expert, has praised remdesivir, saying it would set "a new standard of care" for patients.

WHO tells doctors not to use Gilead's remdesivir as a coronavirus treatment, splitting with FDA

Gilead (GILD) announces successful top-line results from a phase I/II study on its investigational, long-acting HIV-1 capsid inhibitor.

Gilead (GILD) Reports Positive Top-Line Data on HIV Candidate

Let's see if Gilead Sciences (GILD) stock is a good choice for value-oriented investors right now from multiple angles.

Should Value Investors Choose Gilead Sciences (GILD) Stock?

Pfizer, Inc. (PFE), BioNTech SE (BNTX), Eli Lilly and Company (LLY), AstraZeneca plc (AZN), Moderna, Inc. (MRNA) and Gilead Sciences, Inc. (GILD) are leading the race to come up with a vaccine for coronavirus.

What Awaits Pharma Giants in Last Lap of COVID-19 Vaccine Race?

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced topline results from the Phase 2/3 CAPELLA trial evaluating the company's investigational, long-acting HIV-1 capsid inhibitor, lenacapavir, in heavily treatment-experienced people with multidrug resistant HIV-1 infection. The study found that 88% of participants receiving lenacapavir (n=21/24) experienced at least a 0.5 log10 reduction in HIV-1 viral load by the end of 14 days of functional monotherapy as

Gilead Announces Investigational Long-Acting HIV-1 Capsid Inhibitor, Lenacapavir, Achieves Primary Endpoint in Phase 2/3 Study in Heavily Treatment-Experienced People Living With HIV

Low earnings and weak revenues have devastated Gilead stock, leaving it near a 5-year low. However, the firm's wide economic moat in certain drug markets, robust drug pipeline, and COVID-19 medicine create attractive growth opportunities for the future.

Gilead: A Gilded Future From Its Drug Pipeline

Novo Nordisk

Gilead (GILD) and Novo Nordisk present favorable outcomes from a mid-stage study in NASH patients.

Gilead (GILD), Novo Nordisk Post Upbeat Data From NASH Study

Pfizer's surprisingly strong initial Covid-19 vaccine efficacy data that came out last week probably marks the beginning of the end of the Covid-19 pandemic. While this is very positive for the economy and the broader stock market, what does it mean for companies that sell or are developing.

Eli Lilly, Regeneron, Gilead: What The Vaccine Means For Covid-19 Treatment Stocks

FOSTER CITY, Calif. & BAGSVÆRD, Denmark--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Novo Nordisk A/S (NASDAQ Copenhagen: NOVO B) today announced results from a Phase 2 proof-of-concept trial. The five-arm trial evaluated combinations of Novo Nordisk's semaglutide, a GLP-1 receptor agonist, with Gilead's investigational FXR agonist cilofexor and/or Gilead's investigational ACC inhibitor firsocostat over 24 weeks in 108 people with non-alcoholic steatohepatitis (NASH). The results

Gilead and Novo Nordisk Present New Data from Proof-of-Concept Trial in NASH

Gilead Sciences has seen the stock fall to multi-year lows as the Remdesivir excitement disappears. Acquisition of Immunomedics adds to the growth profile of the biopharma.

Gilead Sciences: Back In The Growth Game

Gilead's coronavirus treatment, Veklury, shouldn't be used routinely in critically ill patients, according to a top intensive care doctor. Gilead stock has been on a downtrend since July.

News for Gilead Sciences Stock (GILD)